Validation of the Swedish Diabetes Re-Grouping Scheme in Adult-Onset Diabetes in China.

<bold>Context: </bold>This study applied the Swedish novel data-driven classification in Chinese newly diagnosed diabetic patients and validated its adoptability.<bold>Objective: </bold>This study aimed to validate the practicality of the Swedish diabetes regrouping scheme in Chinese adults with newly diagnosed diabetes.<bold>Design: </bold>Patients were classified into 5 subgroups by K-means and Two-Step methods according to 6 clinical parameters.<bold>Setting: </bold>Ambulatory care.<bold>Patients: </bold>A cross-sectional survey of 15 772 patients with adult-onset newly diagnosed diabetes was conducted in China from April 2015 to October 2017.<bold>Intervention: </bold>None.<bold>Main Outcome Measures: </bold>Six parameters including glutamate decarboxylase antibodies (GADA), age of onset, body mass index (BMI), glycated hemoglobin A1c (HbA1c), homoeostatic model assessment 2 estimates of β-cell function (HOMA2-B) and insulin resistance (HOMA2-IR) were measured to calculate the patient subgroups.<bold>Results: </bold>Our patients clustered into 5 subgroups: 6.2% were in the severe autoimmune diabetes (SAID) subgroup, 24.8% were in the severe insulin-deficient diabetes (SIDD) subgroup, 16.6% were in the severe insulin-resistance diabetes (SIRD) subgroup, 21.6% were in the mild obesity-related diabetes (MOD) subgroup and 30.9% were in the mild age-related diabetes (MARD) subgroup. When compared with the Swedish population, the proportion of SIDD subgroup was higher. In general, Chinese patients had younger age, lower BMI, higher HbA1c, lower HOMA2-B and HOMA2-IR, and higher insulin use but lower metformin usage than the Swedish patients.<bold>Conclusion: </bold>The Swedish diabetes regrouping scheme is applicable to adult-onset diabetes in China, with a high proportion of patients with the severe insulin deficient diabetes. Further validations of long-term diabetes complications remain warranted in future studies. [ABSTRACT FROM AUTHOR]